首页> 外文期刊>臨床病理 >Analysis of the Plasma Concentration of Tacrolimus: A Useful Method for Distinguishing Falsely Elevated Tacrolimus Concentrations Reported by the ACMIA
【24h】

Analysis of the Plasma Concentration of Tacrolimus: A Useful Method for Distinguishing Falsely Elevated Tacrolimus Concentrations Reported by the ACMIA

机译:他克莫司的血浆浓度分析:区分ACMIA报告的错误升高的他克莫司浓度的一种有用方法

获取原文
获取原文并翻译 | 示例
           

摘要

Tacrolimus monitoring is essential because tacrolimus has a narrow therapeutic dose range. A 35-year-old male after kidney transplantation showed unusually high tacrolimus concentrations in the affinity column mediated immunoassay (ACMIA).Methods: His whole blood tacrolimus concentrations were measured by the ACMIA, microparticle enzyme immunoassay (MEIA), enzyme-linked immunosorbent assay (ELISA) , and the enzyme multiplied immunoassay technique (EMIT). Since the findings were discrepant, the possible causes were investigated. To screen for endogenous ^-galactosidase, the cyclosporin A concentration of the patient's sample was measured by ACMIA. To determine whether the false increase was attributable to his plasma, tacrolimus concentrations were measured in the whole blood and plasma of the patient in question and 3 other patients. To eliminate heterophilic antibodies, the patient's plasma was treated with heterophilic blocking tube. To eliminate immunoglobulin interference, the patient's plasma was incubated with Protein A or G. Results and Discussion: The patient's tacrolimus concentration was found to be 16.4, 3.7, 3.2, and 3.0mug/L by the ACMIA, MEIA, ELISA, and EMIT, respectively. In the cyclosporin assay, the absorbance did not increase; therefore, beta-galactosidase participation was ruled out. Tacrolimus is mainly sequestered in erythrocytes; however, this patient's plasma and whole blood showed similar tacrolimus levels. Heterophilic blocking tube did not affect the patient's tacrolimus level. His tacrolimus concentration was reduced after incubation with Protein A, indicating that immunoglobulins trapped by Protein A had non-specifically interfered with the assay system.Conclusion: When the tacrolimus level indicated by the ACMIA is unexpectedly high, the patient's plasma should be assayed. If the tacrolimus plasma level is subsequently found to be high, the original result might be incorrect, and it is recommended that another method be used.
机译:他克莫司的监测是必不可少的,因为他克莫司的治疗剂量范围很窄。肾移植后一名35岁男性在亲和柱介导的免疫分析(ACMIA)中显示他克莫司浓度异常高。 (ELISA)以及酶联免疫测定技术(EMIT)。由于发现不一致,因此调查了可能的原因。为了筛选内源性β-半乳糖苷酶,通过ACMIA测量患者样品的环孢菌素A浓度。为了确定错误的增加是否归因于他的血浆,在所述患者和其他3名患者的全血和血浆中测量了他克莫司的浓度。为了消除嗜异性抗体,用嗜异性阻断管治疗患者的血浆。为了消除免疫球蛋白干扰,将患者血浆与蛋白A或G孵育。结果与讨论:通过ACMIA,MEIA,ELISA和EMIT发现患者的他克莫司浓度为16.4、3.7、3.2和3.0mug / L。分别。在环孢菌素测定中,吸光度没有增加。因此,排除了β-半乳糖苷酶的参与。他克莫司主要被隔离在红细胞中。但是,该患者的血浆和全血显示出他克莫司水平相似。嗜异性阻断管未影响患者的他克莫司水平。与蛋白A孵育后,他克莫司的浓度降低,表明蛋白A捕获的免疫球蛋白对测定系统有非特异性干扰。结论:当ACMIA指示的他克莫司水平出乎意料地高时,应测定患者的血浆。如果随后发现他克莫司的血浆水平较高,则原始结果可能不正确,建议使用其他方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号